OPK experienced a dramatic financial reversal with net income swinging from $21.6M profit to -$225.7M loss despite quadrupling revenue to $606.9M.
This massive earnings deterioration alongside explosive revenue growth suggests either significant one-time charges, acquisition-related costs, or fundamental profitability challenges that warrant immediate investor attention. The 87 million share increase (13% dilution) combined with the earnings collapse indicates potential equity financing to fund operations or acquisitions.
OPK's financial profile shows a company in transition with revenue surging 300% to $606.9M while net income collapsed into deep losses of -$225.7M, representing an over 1,100% negative swing. The company improved its balance sheet strength by reducing total debt 21% and current liabilities 24%, while share count increased significantly by 13%, suggesting equity dilution to fund growth or operations. Despite the revenue explosion, the dramatic earnings deterioration combined with increased R&D spending signals either major one-time costs or challenges monetizing the rapid top-line expansion.
Net income declined 1143.3% — review whether driven by operations, interest costs, or non-recurring items.
Strong top-line growth of 300.1% — accelerating demand or successful expansion into new markets.
Buyback activity reduced 47.9% — capital being redeployed elsewhere or cash conservation underway.
SG&A reduced 26.7% — improved cost efficiency or headcount reduction improving operating margins.
Current liabilities reduced — improved short-term financial position and working capital health.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
Debt reduced 21.3% — deleveraging strengthens balance sheet and reduces financial risk.
Liabilities reduced 20.5% — deleveraging improves balance sheet strength and financial flexibility.
R&D investment increased 17.9% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →